Department of Gastrointestinal Surgery, Zhejiang Provincial Hospital of TCM, Hangzhou, Zhejiang, PR China.
Medical Department, Shanghai Roche Pharmaceutical Company, Shanghai, PR China.
Future Oncol. 2018 Apr;14(8):771-779. doi: 10.2217/fon-2017-0558. Epub 2017 Dec 18.
In China, the treatment of locally advanced gastric cancer (AGC) faces unique challenges. Chinese patients may harbor more unfavorable prognostic factors than western populations and, in comparison with other Asian populations such as Japan and South Korea, a higher proportion of Chinese patients are diagnosed with AGC due to inadequate early diagnosis of the malignancy. This review summarizes the use of combination chemotherapy regimens with capecitabine as adjuvant therapy in the Chinese AGC population. Based on the available domestic data in China, the review concludes that capecitabine-based chemotherapy regimens, especially XELOX, offer good efficacy following radical gastrectomy in patients with AGC, with a low incidence of adverse events, acceptable tolerance, greater patient convenience and a lower overall cost than other regimens.
在中国，局部晚期胃癌（AGC）的治疗面临着独特的挑战。中国患者可能比西方人群具有更多不利的预后因素，与日本和韩国等其他亚洲人群相比，由于恶性肿瘤的早期诊断不足，中国患者中 AGC 的诊断比例更高。本综述总结了卡培他滨联合化疗方案作为中国 AGC 人群辅助治疗的应用。基于中国国内现有的数据，本综述得出结论，XELOX 等卡培他滨为基础的化疗方案在根治性胃切除术后为 AGC 患者提供了良好的疗效，不良事件发生率低，耐受性可接受，患者更方便，总费用低于其他方案。
